University of Kansas Cancer Center

Kansas City, Kansas
Professor, Department of Cancer Biology
Hall Family Professorship in Molecular Medicine
Adjunct faculty of Department of Molecular & Integrative Physiology


Dr. Welch is a leader in the field of cancer metastasis. With support from NFCR since 1996, his team is identifying the mechanisms underlying how cancer spreads (metastasis) throughout the body from a primary tumor. Metastasized cancer leads to pain, weight loss, bleeding and impairment of organ function. More importantly, nearly 90% of cancer related deaths are due to metastasized cancer. Dr. Welch is leading a novel charge to prevent the spread of cancer by predicting how and what triggers the initiation of metastasis. He and his team are using state-of-the-art molecular biology techniques to explore the expression of biomarkers produced by metastatic and non-metastatic cancer cells in order to predict which cancer will metastasize. In addition, Dr. Welch and his laboratory discovered eight genes that get turned off when cancer cells become metastatic cells and can lead to therapeutics that arrest metastasis.

This two-pronged approach will permit Dr. Welch to not only develop novel metastatic cancer markers to assess a patient’s likelihood of developing metastasis, but also to develop unique anti-metastasis therapies. His current research regarding cancer metastasis has high impact for patients with breast, lung, ovarian, pancreatic, prostate, kidney and skin cancer.


Danny R. Welch, Ph.D., received his bachelor’s degree in biology from the University of California at Irvine and a Ph.D. from the University of Texas-Houston in tumor biology. Following his doctoral research, he became a research scientist at the Upjohn Company and Glaxo pharmaceuticals. At both companies, he was responsible for pre-clinical testing of anti-cancer drugs. In 1990, he joined the faculty of the Pennsylvania State University College of Medicine where he ascended the faculty ranks to the level of Associate Professor. In 2002, Dr. Welch joined the faculty of the University of Alabama at Birmingham as a Professor of Pathology and Director of the Metastasis Program at the Comprehensive Cancer Center.

From 2002-2018, Dr. Welch led the NFCR Center for Cancer Metastasis. In 2011, he founded the Department of Cancer Biology at Kansas University Medical Center. Moreover, Dr. Welch is a Komen scholar and president of the Cancer Biology Training Consortium. He has served on numerous grant review panels for the National Institutes of Health, Department Of Defense, American Cancer Society the Susan G. Komen organization, the European Union and other international agencies.

Dr. Welch has served as editor-in-chief for Clinical and Experimental Metastasis and is currently a deputy editor at Cancer Research. He is also co-editor of the textbook Cancer Metastasis. Throughout his career, Dr. Welch has authored more than 200 peer-reviewed publications and more than 35 book chapters, and he’s the recipient of numerous mentoring and teaching awards.

Related Content

Exercise Training May Slow Tumor Growth and Improve Immunotherapy Outcomes in Breast Cancer Treatment

Exercise plays an important role in preventing a variety of cancers. A recent study has increased the importance of maintaining a well-balanced and active lifestyle – indicating a positive outlook for many breast cancer patients.  National Foundation for Cancer Research (NFCR)-funded scientist Dr. Rakesh Jain, and his team at Massachusetts General Hospital and Harvard Medical School found that exercise training may slow tumor growth and improve outcomes for females with breast cancer – especially those treated with immunotherapy drugs. Immunotherapy drugs are treatments that use the body’s immune system to fight diseases like cancer. The research team identified this occurrence to be caused by stimulating naturally occurring immune mechanisms.   The team reached this conclusion in animal models of breast cancer, which showed physical activity increasing levels of cancer-fighting immune cells. Tumors in mouse models of human breast cancer grew more slowly in mice put through their paces in a structured aerobic exercise program than in sedentary mice. The tumors in exercised mice exhibited an increased anti-tumor immune response. Perhaps the most exciting finding of the study was that exercise training brought immune cells capable of killing cancer cells into tumors. The tumors grew more slowly in mice that performed exercise training. Dr. Jain has been an NFCR partner since 1998. He is a renowned world expert in understanding how changes in the microenvironment surrounding tumors affect the immune system, drug delivery, treatment efficacy, and patient survival–with additional expertise in chemical engineering. In addition to his fellowship with NFCR, Dr. Jain is an elected member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. He is the ninth person ever to be elected to all three U.S. National Academies. He is also a Fellow of the American Association for Cancer Research (AACR) Academy. Throughout his career, Dr. Jain has also been the recipient of numerous prestigious awards. Including the 2012 Science of Oncology Award from the American Society of Clinical Oncology and the 2016 National Medal of Science from the President of the United States, Barack Obama. He received the Medal of Science for developing new ways to manipulate tumors. Dr. Jain and his team at Massachusetts General Hospital and Harvard Medical School were able to complete this game-changing research utilizing funding from NFCR. NFCR is dedicated to providing scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection, and ultimately, to discover a cure for all types of cancer.  Support innovative and life-saving research findings like the work of Dr. Jain with NFCR. Additional Reads You May Enjoy: NFCR-Supported Researcher Leads Study Aiming to Understand Which Patients May Respond Best to Immunotherapy Immunotherapy: Fighting Cancer and More? Cancer Research Applied to Develop COVID-19 Treatment Strategies Stay connected with the cancer community! Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Melanoma 101: What You Need to Know

Skin cancer diagnoses are growing at an alarming rate.  In fact, over the past three decades, more people have been diagnosed with some form of skin cancer than all other cancers combined. Melanoma, an aggressive form of skin cancer, is the deadliest type.  Many cases of melanoma can be prevented. To protect yourself and your loved ones here is all you need to know about the deadly melanoma skin cancer.  First off, what is it? Melanoma develops from melanocytes or the skin cells that produce melanin pigment, which gives the skin its color.  Melanoma can develop anywhere melanocytes are found, but certain areas are more prone than others. In men, it is most likely to affect the back and the head and neck area. In women, the legs are the most common site.  What causes melanoma skin cancer? Melanoma forms when something goes wrong in the melanocytes. When the DNA in these cells becomes damaged, they may begin to grow out of control. Experts believe that 90% of all melanomas are caused by ultraviolet (UV) radiation from the sun or indoor tanning devices.  How common is it? In 2021, over 200,000 cases of melanoma skin cancer will be diagnosed in the United States. Of those, 101,280 cases will be in situ (noninvasive), confined to the top layer of skin (the epidermis), and 106,110 cases will be invasive, penetrating the epidermis into the skin’s second layer (the dermis). The number of new cases of melanoma cancer has steadily increased for the last 30 years.  How can one stay protected from melanoma skin cancer? As most melanoma skin cancers are caused by UV radiation, the most important thing a person can do is protect themselves from the sun and avoid tanning beds.  It is important to remember that protection from UV radiation is important all year round and among all various weather conditions. The Center for Disease Control and Prevention states that the sun can be exceptionally damaging between the hours of 10 am and 4 pm Daylight Savings Time (9 am to 3 pm standard time). During this time, it is recommended that people stay in the shade, wear clothing that covers arms and legs, wear a hat, wear sunscreen, and wear sunglasses.  What is a melanoma mole? Melanoma skin cancer often resembles moles and sometimes may arise from them. They can be found on any area of the body, even in areas that are not typically exposed to the sun. For this reason, it is important to know the color, size, and location of moles on one’s body to ensure any changes are noticed.  What research is currently being done on melanoma skin cancer? The National Foundation for Cancer Research (NFCR) is committed to fighting cancer by funding high-risk, high-impact, and high-reward discoveries for cancer patients. Dr. Helmut Sies, an NFCR-funded researcher, is making great strides in melanoma skin cancer research.  After years of studying the role of micronutrients in cancer prevention, Dr. Sies discovered that lycopene, a carotenoid and antioxidant found in tomatoes and carrots, can reduce the damaging effects of oxygen produced by our body’s essential metabolic processes, and has strong skin cancer prevention effects. His research also […]

Phase II Clinical Trials May Be on the Way for Ovarian Cancer

Dubbed one of the notorious ‘silent killers’, ovarian cancer claims the lives of approximately 14,000 American women each year. Tragically, all women are at risk and early detection and sustainable treatment have proved to be difficult. However, a recent study provides new hope in the realm of ovarian cancer treatment. Women who are diagnosed with ovarian cancer are commonly prescribed two chemotherapy drugs: paclitaxel and carboplatin. When a patient’s body resists these drugs, she is left with few options for continued ovarian cancer treatment. For those who do not experience initial resistance, the looming threat of recurrence suggests future difficulties. Thankfully, the ominous outlook for ovarian cancer treatment is looking brighter thanks to physician-scientist Robert C Bast, Jr, MD., and his past support from the National Foundation for Cancer Research (NFCR).  Acknowledging early funding from the NFCR, Dr. Bast has recently published his research results that provide substantial hope for women undergoing ovarian cancer treatment. In this study Dr. Bast explains that while carboplatin and paclitaxel can be a strong first-line treatment for ovarian cancer, the drugs are curing less than 20% of advanced stage ovarian cancer. However, a small molecule inhibitor can improve the response to paclitaxel in ovarian cancer cells and complex models during the pre-clinical research and the combined treatment is being used now in a Phase I trial for ovarian cancer. In the current paper, the research team discovered that the inhibitor increased carboplatin’s ability to induce DNA-damage and apoptosis (cell suicide), simply meaning the drug’s ability to kill cancerous cells improved. Dr. Bast continues to explain that discovering the impact of the molecular inhibitor on carboplatin provides an exciting outlook for upcoming clinical trials for ovarian cancer treatment. If the ongoing Phase I trial treating ovarian cancer patients with the combination of paclitaxel and the inhibitor goes well, a Phase I/II trial may be initiated using the molecule inhibitor and carboplatin. This exciting discovery suggests that women undergoing ovarian cancer treatment may have a more promising outlook, especially those who experience resistance to carboplatin and paclitaxel or have a recurrence of ovarian cancer. NFCR continues to support world leaders in ovarian cancer research. Amongst these current and past funded scientists are Dr. Danny Welch, Dr. Wei Zhang, Dr. Susan Horwitz, Dr. Amos B. Smith III, and Dr. Harold F. Dvorak. Each dedicated NFCR-funded researcher is committed to game-changing discoveries in cancer treatments, detection, and ultimately, a cure. Visit National Foundation for Cancer Research to learn how you can play a role in supporting world leaders in cancer research. Additional Reads You May Enjoy: Genetic Cues to Ovarian Cancer Explored The Development of Better Ovarian Cancer Biomarkers 5 Warning Signs Women Shouldn’t Ignore Stay connected with us! Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips and more. Sign up here.